NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
12/24/2024
Back to search
Official data from USPTO
MODAGIN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
MODAGIN
ST13
US500000097828693Class
5, 42, 44
Filing
97828693
Registration
7617828
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
19
Latest update
12/24/2024
Trademark type
Word
Nice classes
5, 42, 44
Filing date
03/08/2023
Registration date
12/24/2024
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
12/24/2024
Last transaction
12/24/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
Drawing code
4
Owner type
99
Owner location
Wendelsheim, DE
Examiner
SMITH, BRENDAN
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
MODAG GmbH
Representatives
Ralph G. Fischer Buchanan Ingersoll & Rooney PC
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicines for human medical purposes in the nature of pharmaceutical preparations for the use in the treatment of neurodegenerative diseasesAlzheimer's diseasecardiovascular and cerebrovascular diseasescentral nervous systemParkinson's disease; Medicines for veterinary purposes for treatment of neurodegenerative diseasesAlzheimer's diseasecardiovascular and cerebrovascular diseasescentral nervous systemParkinson's disease; Pharmaceuticals and natural remediesnatural remedy preparations for the treatment of neurodegenerative diseasesAlzheimer's diseasecardiovascular and cerebrovascular diseasescentral nervous systemParkinson's disease; Medicines for the treatment of Alzheimer's disease; Medicines for the treatment of neurodegenerative diseases; Medicines for the treatment of cardiovascular and cerebrovascular diseases; Chemical-pharmaceutical preparations for the treatment of neurodegenerative diseasesAlzheimer's diseasecardiovascular and cerebrovascular diseasescentral nervous systemParkinson's disease; Chemical reagents for medical or veterinary purposes; Diagnostic preparations for medical or veterinary purposes; Diagnostic preparations and materials for medical purposes; Diagnostic biomarker reagents for medical purposes; Diagnostic reagents for medical purposes; Injectable pharmaceuticals for the treatment of neurodegenerative diseasesAlzheimer's diseasecardiovascular and cerebrovascular diseasescentral nervous systemParkinson's disease; Medicinal preparations and substances for the treatment of neurodegenerative diseasesAlzheimer's diseasecardiovascular and cerebrovascular diseasescentral nervous systemParkinson's disease; Agents against Parkinson's diseasepharmaceutical agents for the treatment of Parkinson's disease; Pharmaceutical medicines in the nature of pharmaceutical preparations for the treatment of neurodegenerative diseasesAlzheimer's diseasecardiovascular and cerebrovascular diseasescentral nervous systemParkinson's disease; Pharmaceutical products for the treatment of neurodegenerative diseasesAlzheimer's diseasecardiovascular and cerebrovascular diseasescentral nervous systemParkinson's disease; Pharmaceutical preparations for human use for the treatment of neurodegenerative diseasesAlzheimer's diseasecardiovascular and cerebrovascular diseasescentral nervous systemParkinson's disease; Pharmaceutical preparations for the treatment of Parkinson's disease; Pharmaceutical preparations for the treatment of Alzheimer's disease; Pharmaceutical preparations for the treatment of neurodegenerative diseases; Pharmaceutical preparations for the treatment of cerebral disease; Pharmaceutical preparations for the treatment of central nervous system diseases
Class 42
Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Consultancy relating to pharmaceutical research and development; Biological researchclinical research and medical research in the field of pharmaceuticals; Medical research laboratory services; Conducting technical tests on pharmaceuticals; Conducting analysis of human serum for medical research; Conducting analysis of human tissues for medical research; Development of pharmaceutical preparations and medicines; Pharmaceutical products development; Research and development of vaccines and medicines; Providing scientific information in the field of medical disorders and their treatment; Research in the field of pharmacogenetics; Research relating to pharmaceuticals; Research and development in the field of pharmacy and biotechnology; Clinical research in the field of pharmaceuticals; Laboratory research services relating to pharmaceuticals; Medical research; Medical and pharmacological research services; Pharmaceutical drug development services; Pharmaceutical research services; Pharmaceutical research and development; Quality testing for pharmaceutical products; Scientific research in the field of pharmacy; Scientific research and development
Class 44
Medication counseling; Providing information to patients in the field of administering medications; Providing medical information relating to pharmaceutical products; Providing information relating to the treatment of degenerative diseases; Providing information relating to medical services; Medical advisory services relating to degenerative diseases; Medical consultancy and medical information services relating to pharmaceutical products; Medical consultancy and medical information services relating to pharmaceutical products provided via the Internet; Medical consultancy and medical information services relating to medical products; Medical consultancy services relating to medicines; Medical services; Medical services for the treatment of Alzheimer's disease; Pharmaceutical compounding services; Preparation and administration of medicines being medical services
Publications
History of USPTO decisions and trademark events.
19 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
12/24/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/22/2024
PUBO
PUBLISHED FOR OPPOSITION
10/22/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/02/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/13/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/11/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/11/2024
ALIE
ASSIGNED TO LIE
08/10/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/25/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/25/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/25/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/23/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/07/2023
GNRT
NON-FINAL ACTION E-MAILED
12/07/2023
CNRT
NON-FINAL ACTION WRITTEN
12/07/2023
DOCK
ASSIGNED TO EXAMINER
12/06/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/28/2023
NWAP
NEW APPLICATION ENTERED
03/11/2023
Continuous trademark protection
Get notified about every new filing that threatens MODAGIN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.